TY  - JOUR
AU  - Tigu, Adrian-Bogdan
AU  - Nistor, Madalina
AU  - Gulei, Diana
AU  - Constantinescu, Catalin-Sorin
AU  - Kegyes, David
AU  - Cenariu, Diana
AU  - Muresan, Ximena
AU  - Munteanu, Raluca
AU  - Feder, Richard
AU  - Jitaru, Ciprian
AU  - Bancos, Anamaria
AU  - Santa, Maria
AU  - Tomai, Radu
AU  - Damian, Marc
AU  - Ivancuta, Andrei
AU  - Rus, Ioana
AU  - Bojan, Anca
AU  - Zdrenghea, Mihnea
AU  - Buzoianu, Anca-Dana
AU  - Tanase, Alina
AU  - Einsele, Hermann
AU  - Kobold, Sebastian
AU  - Tomuleasa, Ciprian
TI  - CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases.
JO  - Blood reviews
VL  - nn
SN  - 0268-960X
CY  - Burlington, Mass.
PB  - Harcourt
M1  - DKFZ-2025-02662
SP  - nn
PY  - 2025
N1  - epub
AB  - Chimeric Antigen Receptor (CAR) T cell therapy, initially developed for hematologic malignancies, has recently emerged as a promising modality for treating autoimmune diseases. This review explores the evolving role of CAR T cells in reprogramming immune tolerance and achieving durable remission in autoimmune disorders. By engineering T cells to target pathogenic B cells or autoreactive T cells, CAR T therapy offers a targeted and potentially curative approach for diseases such as systemic lupus erythematosus, multiple sclerosis, and type 1 diabetes. Early clinical trials and preclinical models have demonstrated the feasibility, safety, and efficacy of CD19-targeted CAR T cells in depleting autoreactive B cells and restoring immune homeostasis. Furthermore, next-generation CAR designs-including regulatory T cell-based CARs and antigen-specific constructs-highlight the growing precision and versatility of this platform. Despite these advances, challenges remain, including potential toxicity, antigen escape, and the need for long-term immune monitoring. This review summarizes current findings, delineates mechanistic insights, and discusses future directions for optimizing CAR T cell therapies in the context of autoimmunity.
KW  - Autoimmune diseases (Other)
KW  - CAR T cells (Other)
KW  - Emerging therapies (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41318274
DO  - DOI:10.1016/j.blre.2025.101354
UR  - https://inrepo02.dkfz.de/record/306669
ER  -